Clinical Trials for Colon Cancer

Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with microsatellite-stable colorectal cancer and peritoneal-predominant metastases not suitable for curative cytoreduction/HIPEC, after progression on or intolerance to at least one standard systemic chemotherapy, receive lymphodepleting cyclophosphamide/fludarabine. Treatment is dual IV and intraperitoneal TROP2-directed CAR-NK cells engineered to express IL-15 and lack TGFBR2, combined with IV cetuximab to target EGFR and potentially enhance NK-cell ADCC.

ClinicalTrials.gov ID: NCT07411599

Phase 1 Single Center Study to Evaluate Safety and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Single Agent Mitomycin C (MMC) in Peritoneal Carcinomatosis (PC) From Solid Gastrointestinal Malignancies (sGI-PC) in Palliative Setting

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable peritoneal carcinomatosis from colorectal, small-bowel, or high-grade appendiceal adenocarcinoma who have received at least 4 months of first-line 5-FU–based therapy and cannot undergo or decline cytoreductive surgery and HIPEC receive up to three laparoscopic treatments with pressurized intraperitoneal aerosolized mitomycin C while continuing 5-fluorouracil/leucovorin. Mitomycin C is a DNA-cross-linking cytotoxic agent; this study evaluates its dose and safety when delivered by PIPAC.

ClinicalTrials.gov ID: NCT07487168

Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, unresectable locally advanced or metastatic pancreatic, non-small cell lung, HR+/HER2− breast, or triple-negative breast cancer—and colorectal cancer during dose escalation only—undergo screening with the FAP-targeted PET tracer [68Ga]Ga-NNS309. Patients with tracer-avid tumors receive [177Lu]Lu-NNS309, a FAP-targeted radioligand that delivers beta radiation to tumor stroma and nearby cancer cells.

ClinicalTrials.gov ID: NCT06562192

A Phase 1b/2a Multi-Center, Dose Escalation and Reference Regimen-Controlled, Multi-Cohort Study to Determine the Safety and Efficacy of Oral 7HP349 (Alintegimod) in Combination with Ipilimumab Followed by Nivolumab Monotherapy in Patients with Locally Advanced or Metastatic Cancers Following One or More Prior Therapies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable, locally advanced or metastatic solid tumors after at least one prior therapy are eligible for the currently enrolling dose-escalation cohorts, including patients previously treated with anti–PD-1/PD-L1 therapy. Treatment is oral alintegimod, an investigational LFA-1/VLA-4 integrin agonist, initially alone and then with ipilimumab, followed by nivolumab monotherapy.

ClinicalTrials.gov ID: NCT06362369

A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplifications

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic solid tumors harboring a KRAS mutation or high-level KRAS wild-type amplification receive the investigational oral pan-KRAS inhibitor BGB-53038 alone or with tislelizumab (anti–PD-1) for nonsquamous NSCLC or cetuximab (anti-EGFR) for colorectal cancer. The study has been terminated, in part because of a lack of promising efficacy.

ClinicalTrials.gov ID: NCT06585488

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults and adolescents with advanced or metastatic solid tumors (including NSCLC) harboring ALK, ROS1, or NTRK1-3 gene rearrangements to receive repotrectinib, a next-generation oral tyrosine kinase inhibitor designed to overcome resistance mutations in these oncogenic fusions. Eligible patients may have received prior TKIs and may have asymptomatic CNS metastases.

ClinicalTrials.gov ID: NCT03093116

A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally advanced or metastatic KRAS G12D-mutated solid tumors, including pancreatic, colorectal, and non-small cell lung cancers, receive the oral KRAS G12D inhibitor INCB161734 alone or with cetuximab, retifanlimab, gemcitabine/nab-paclitaxel, or modified FOLFIRINOX. Prior KRAS G12D inhibitor treatment is excluded.

ClinicalTrials.gov ID: NCT06179160

A Phase 1/1b Multiple Cohort Trial of ALTA3263 in Patients With Advanced Solid Tumors With KRAS Mutations

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable or metastatic KRAS-mutant solid tumors who have progressed on, cannot tolerate, or declined appropriate standard therapy receive oral ALTA3263. This investigational KRAS isoform-selective inhibitor is designed to bind mutant KRAS in both active and inactive states, including G12V, G12D, and G12C.

ClinicalTrials.gov ID: NCT06835569

A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced KRAS-mutated solid tumors and ECOG 0–1, including PDAC, CRC, and NSCLC, receive oral PF-07934040, an investigational pan-KRAS inhibitor, either alone in later-line cohorts or with standard agents in tumor-specific cohorts. First-line combinations include gemcitabine/nab-paclitaxel for PDAC, FOLFOX/bevacizumab for CRC, and pembrolizumab with or without platinum chemotherapy for NSCLC; later-line CRC may receive PF-07934040 plus cetuximab.

ClinicalTrials.gov ID: NCT06447662

An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants with KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with KRAS G12C-mutated locally advanced unresectable or metastatic solid tumors who have progressed on or cannot receive standard therapy receive oral FMC-376, an investigational inhibitor designed to covalently target both active and inactive KRAS G12C.

ClinicalTrials.gov ID: NCT06244771